» Articles » PMID: 38534280

Screening for High-Risk Human Papillomavirus Reveals HPV52 and HPV58 Among Pediatric and Adult Patient Saliva Samples

Overview
Journal Dent J (Basel)
Specialty Dentistry
Date 2024 Mar 27
PMID 38534280
Authors
Affiliations
Soon will be listed here.
Abstract

Previous research has demonstrated that the human papillomavirus (HPV) can infect a wide range of human tissues, including those within the oral cavity. High-risk oral HPV strains have been associated with the development and progression of oral cancers, including oral squamous cell carcinomas. Although many studies have examined the prevalence of the high-risk strains HPV16 and HPV18, far fewer have assessed the prevalence of other high-risk HPV strains. An approved study protocol was used to identify HPV52 and HPV58 among clinical samples ( = 87) from a saliva biorepository. Quantitative polymerase chain reaction (qPCR) and validated primers for HPV52 and HPV58 were used to facilitate this screening. This screening demonstrated that a total of = 4/45 or 8.9% of adult saliva samples harbored high-risk HPV52, and = 2/45 or 4.4% tested positive for high-risk HPV58. In addition, a total of = 6/42 or 14.3% of the pediatric saliva samples tested positive for high-risk HPV, including = 5/42 or 11.9% with HPV52 and = 3/42 or 7.1% for HPV58. These data demonstrate the presence of the high-risk oncogenic HPV52 and HPV58 strains among both adult and pediatric clinical patient samples. More detailed longitudinal research must be conducted to determine whether this prevalence may be increasing or decreasing over time. In addition, these data strongly support public health prevention efforts, such as knowledge and awareness of the nine-valent HPV vaccine covering additional high-risk strains, including HPV52 and HPV58.

Citing Articles

Longitudinal Screening for Oral High-Risk Non-HPV16 and Non-HPV18 Strains of Human Papillomavirus Reveals Increasing Prevalence among Adult and Pediatric Biorepository Samples: A Pilot Study.

Jacobs J, Chon E, Kingsley K Vaccines (Basel). 2024; 12(8).

PMID: 39204021 PMC: 11360083. DOI: 10.3390/vaccines12080895.

References
1.
Kumari B, Ali A, Sharma A, Gehlot A, Sharma S . Non-invasive saliva-based screening of high-risk Human Papilloma Virus 16 and 18 in healthy young adults and creating awareness about its vaccination. J Family Med Prim Care. 2021; 10(1):387-391. PMC: 8132784. DOI: 10.4103/jfmpc.jfmpc_1669_20. View

2.
Volesky K, El-Zein M, Franco E, Brenner D, Friedenreich C, Ruan Y . Cancers attributable to infections in Canada. Prev Med. 2019; 122:109-117. DOI: 10.1016/j.ypmed.2019.03.035. View

3.
Lin R, Jin H, Fu X . Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis. Expert Rev Vaccines. 2023; 22(1):1168-1178. DOI: 10.1080/14760584.2023.2287135. View

4.
Alqahtani W, Almufareh N, Al-Johani H, Alotaibi R, Juliana C, Aljarba N . Oral and Oropharyngeal Cancers and Possible Risk Factors Across Gulf Cooperation Council Countries: A Systematic Review. World J Oncol. 2020; 11(4):173-181. PMC: 7430852. DOI: 10.14740/wjon1283. View

5.
Dempsey A, OLeary S . Human Papillomavirus Vaccination: Narrative Review of Studies on How Providers' Vaccine Communication Affects Attitudes and Uptake. Acad Pediatr. 2018; 18(2S):S23-S27. DOI: 10.1016/j.acap.2017.09.001. View